- Global Pharma News & Resources

Pasithea Opens First Clinic in Los Angeles Offering Ground Breaking Ketamine Therapy and Innovative Treatments for Mental Health Disorders

Healthcare company is pioneering new treatments to help patients reclaim their lives

LOS ANGELES--(BUSINESS WIRE)--Pasithea Clinics, a healthcare subsidiary of Pasithea Therapeutics – the novel biotechnology company dedicated to the research and discovery of effective treatments for psychiatric and neurological disorders such as anxiety, depression, and post-traumatic stress disorder (PTSD) – today announced the opening of its Los Angeles, California based clinic. Currently offering at-home treatments in California, Florida, New York, and London, Pasithea will provide a range of scientifically backed protocols, including intravenous (IV) ketamine, SPRAVATO®, psychotherapy, medication management, and traditional psychiatry services to provide life-changing care for those suffering from psychiatric disorders. Treatment for depression and anxiety via transcranial magnetic stimulation (TMS) is coming later this month.

The state-of-the-art 1,235 sq. ft. clinic will be on Sunset Boulevard in Beverly Hills. It will feature four treatment rooms and a team of board-certified doctors, psychiatrists, and anesthesiologists to provide high-quality care to patients suffering from treatment-resistant mental health issues. 1 in 4 Americans is dealing with some sort of mental illness1, with about 40% of people with mental health disorders not responding well to traditional antidepressants (SSRIs). Through its mission to help those suffering from psychiatric conditions, Pasithea is at the forefront of the ketamine therapy evolution by offering patients that meet eligibility requirements access to a team of board-certified doctors who will administer tailored dosages of IV ketamine. Ketamine is a powerful medication that has shown efficacy rates as high as 70%2 for those who suffer from psychiatric conditions and haven’t responded well to other treatments. Ketamine treatment can provide relief within minutes, and most patients feel the results within 24 hours, with no long-term side effects.

Pasithea was founded by two internationally renowned neurology and psychiatry doctors, Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics, and Dr. Lawrence Steinman, Executive Chairman, and Co-Founder. Dr. Marques is a Psychiatrist, and researcher from London, who has published studies for Imperial College, and Kings College, along with running his practice. Dr. Steinman is the endowed chair of neurology and immunology at Stanford University and is a drug development pioneer.

Ketamine is an FDA-approved drug introduced to the medical community as an anesthetic more than 50 years ago, and it has recently been making strides in treating psychiatric disorders. By administering lower doses than in surgeries, researchers have discovered that ketamine has strong antidepressant effects, helping create new synaptic connections between brain cells. This rapid antidepressant effect happens almost immediately while still providing long-lasting relief. Certain psychiatric conditions, such as treatment-resistant depression TRD and PTSD, are highly responsive to IV ketamine and produce a rapid and sustained effect. While the number of treatments suggested is decided on a case-by-case basis, a typical treatment plan consists of up to six infusions in two to three weeks.

“My main goal in life is to provide new solutions for patients needing help with the mental health challenges they are facing,” says Dr. Tiago Marques MD, PhD CEO and Co-Founder of Pasithea. “Pasithea is innovating the way we treat psychiatric disorders and the opening of our Los Angeles clinic is the next step in the revolutionizing care for those who are suffering.”

Ketamine has strong antidepressant effects, stimulating the brain to create new neural pathways and promote positive behavioral patterns. The treatment goes into effect immediately after the first session and continues with five or six sessions for it to be fully in one’s system.

“Searching for the right medication to manage mental health challenges can be a daunting process,” says Dr. Yalda Safai, Tele-health psychiatrist, Pasithea. “The introduction of ketamine therapy to treat mental health conditions has been a revolutionary development that we hadn’t seen in the industry for years. We feel confident that our services will provide hope for those that hadn’t found the right treatment thus far.”

In addition to Pasithea’s Los Angeles clinic, patients can receive in-person care in London and at-home mobile services available in Florida, New York, and California. Pasithea is the only company providing the infrastructure and network to carry out the indicated in an amenable form, accompanied by an experienced team of experts in neuroscience and psychopharmacology.

For more information on Pasithea Clinics, visit

Founded by two internationally renowned neurology and psychiatry doctors, Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics, and Dr. Lawrence Steinman, Executive Chairman, and Co-Founder, Pasithea Clinics is a network of different practices dedicated to tackling the current mental health epidemic and providing unique solutions to patients who suffer from psychiatric and neurological disorders. Pasithea offers ketamine treatments and ongoing care for chronic mental illnesses for treatment-resistant individuals. Their team of board-certified psychiatrists and anesthesiologists are leveraging the latest research backed treatments coupled with the convenience of concierge and telehealth consultations to ensure its patients get the highest level of care in the comfort of their own home. Pasithea’s at-home mobile services are also available in Florida, New York, California and London. Learn more at and @pasitheaclinics.




Editor Details

  • Company:
    • Businesswire
Last Updated: 08-Sep-2022